CBRE GROUP, INC. TO SELL ELI LILLY BIOMANUFACTURING PLANT IN VACAVILLE, CALIFORNIA
Indianapolis, IA (April 20, 2015) — CBRE Group, Inc. announced today that they have been hired to sell Eli Lilly's biomanufacturing plant in Vacaville, California. The highly flexible and multi-purpose facility is one of the largest bulk API manufacturing facilities for recombinant microbial-based biopharmaceuticals in the U.S.
The site includes a 52-acre campus, with 28 acres available for future expansion. The 78,198-square-foot (7,265 square meter) facility includes a state-of-the-art downstream processing building, capable of handling complex purification steps; well-equipped analytical laboratories for raw materials, environmental monitoring and release testing, and a mechanical workshop for equipment maintenance and calibration. A 1 MW solar panel array on site provides low cost electric power to the facility.
CBRE Brokerage Services Life Sciences group will direct the marketing to U.S. and international biopharma firms.
Eli Lilly and Company is an American global pharmaceutical company with headquarters located in Indianapolis. For more information visit www.lilly.com.
For more information about the Vacaville site please contact Jeff Luebker at [email protected] or +1 317 269 1100; Thomas Sullivan at [email protected]
About CBRE Group, Inc.
CBRE Group, Inc. (NYSE:CBG), a Fortune 500 and S&P 500 company headquartered in Los Angeles, is the world's largest commercial real estate services and investment firm (in terms of 2014 revenue). The Company has more than 52,000 employees (excluding affiliates), and serves real estate owners, investors and occupiers through more than 370 offices (excluding affiliates) worldwide. CBRE offers strategic advice and execution for property sales and leasing; corporate services; property, facilities and project management; mortgage banking; appraisal and valuation; development services; investment management; and research and consulting. Please visit our website at www.cbre.com.